Axsome Therapeutics, Inc. 8-K Report: Key Insights from December 30, 2024 Filing

Based on the provided section of the financial report, here are the extracted key pieces of information:

1. Entity Information:

• Company Name: Axsome Therapeutics, Inc.
• CIK: 0001579428
• SEC File Number: 001-37635
• EIN: 45-4241907
• Address: One World Trade Center, 22nd Floor, New York, NY 10007
• Contact Number: (212) 332-3241

2. Document Type:

• Filing Type: 8-K (Current Report)
• Filing Date: December 30, 2024

3. Stock Information:

• Stock Ticker Symbol: AXSM
• Exchange: NASDAQ
• Common Stock Par Value: $0.0001 per share

4. Reporting Period:

• Start Date: December 30, 2024
• End Date: December 30, 2024

Insights:

• The filing is an 8-K, which typically reports significant events that shareholders should know about. This could indicate that there was a noteworthy occurrence within the company on the reporting date.
• Axsome Therapeutics, Inc. is a publicly traded company on NASDAQ, which suggests it is subject to rigorous reporting standards and regulatory scrutiny.
• The report indicates that the financial disclosures are made in accordance with the XBRL format, which is designed to improve the transparency and accessibility of financial data.

This analysis provides a snapshot of the company's current reporting status and essential corporate information that could be relevant for investors and analysts reviewing the company's financial health and market position.